Efficacy of omarigliptin, once-weekly dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes

Figure 4 Change of glucose variability indices from baseline. A: Mean sensor glucose; B: Standard deviation of sensor glucose; C: Mean amplitude of glycemic excursion (MAGE); D: Mean of daily difference (MODD). The Wilcoxon signed rank test was used to determine the differences and degree of significance. L→Om: Switch from linagliptin to omarigliptin; S→Om: Switch from sitagliptin to omarigliptin; V→Om; Switch from vildagliptin to omarigliptin; NS: Not significant; SE: Standard error.